晚期肝细胞癌的治疗，重点在于肝动脉灌注化疗和分子靶向治疗。
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.
出版信息
Liver Cancer. 2012 Sep;1(2):62-70. doi: 10.1159/000342402.
Abstract
Advanced hepatocellular carcinoma is defined as liver cancer with vascular invasion or extrahepatic metastasis that is untreatable by local therapy. In Japan, hepatic arterial infusion chemotherapy (HAIC) with interferon plus 5-fluorouracil (5-FU) or a combination of low-dose 5-FU and cisplatin, referred to as low-dose FP, is administered for treating advanced liver cancer and yields favorable outcomes. Outside Japan, the molecular targeted agent, sorafenib, is used as a first-line treatment for advanced liver cancer. New drug development for advanced liver cancer and clinical trials on combination therapy with sorafenib and HAIC are currently underway. The prognosis of advanced liver cancer will significantly improve if these clinical trials yield positive results.
摘要
晚期肝细胞癌被定义为伴有血管侵犯或肝外转移且无法通过局部治疗治愈的肝癌。在日本，采用干扰素联合5-氟尿嘧啶（5-FU）或低剂量5-FU与顺铂联合（即低剂量FP方案）的肝动脉灌注化疗（HAIC）用于治疗晚期肝癌，并取得了良好疗效。在日本以外地区，分子靶向药物索拉非尼被用作晚期肝癌的一线治疗药物。目前正在进行晚期肝癌的新药研发以及索拉非尼与HAIC联合治疗的临床试验。如果这些临床试验取得阳性结果，晚期肝癌的预后将得到显著改善。
相似文献
1
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy.晚期肝细胞癌的治疗，重点在于肝动脉灌注化疗和分子靶向治疗。
Liver Cancer. 2012 Sep;1(2):62-70. doi: 10.1159/000342402.
2
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.肝动脉灌注化疗与索拉非尼单药治疗晚期肝细胞癌患者的比较。
J Dig Dis. 2015 Sep;16(9):505-12. doi: 10.1111/1751-2980.12267.
3
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.索拉非尼联合低剂量顺铂和氟尿嘧啶肝动脉灌注化疗与索拉非尼单药治疗晚期肝细胞癌的随机、开放标签、3 期试验（SILIUS）
Lancet Gastroenterol Hepatol. 2018 Jun;3(6):424-432. doi: 10.1016/S2468-1253(18)30078-5. Epub 2018 Apr 7.
4
Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.日本肝细胞癌治疗的现状：肝动脉灌注化疗。
Clin Drug Investig. 2012 Aug 8;32 Suppl 2:15-23. doi: 10.1007/BF03265493.
5
Treatment strategies for advanced hepatocellular carcinoma: Sorafenib hepatic arterial infusion chemotherapy.晚期肝细胞癌的治疗策略：索拉非尼与肝动脉灌注化疗。
World J Hepatol. 2018 Sep 27;10(9):571-584. doi: 10.4254/wjh.v10.i9.571.
6
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.比较有大血管侵犯和经导管动脉化疗栓塞耐药状态的晚期肝细胞癌患者行肝动脉灌注化疗和索拉非尼治疗的临床结局。
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.
7
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.肝动脉灌注化疗与索拉非尼治疗晚期肝细胞癌的疗效比较
Liver Cancer. 2020 Sep;9(5):583-595. doi: 10.1159/000508724. Epub 2020 Jul 24.
8
Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.碘油混悬液顺铂联合5-氟尿嘧啶动脉内灌注治疗与索拉非尼治疗对比用于无肝外扩散的伴有肉眼可见血管侵犯的晚期肝细胞癌的临床疗效及安全性：一项前瞻性队列研究
Mol Clin Oncol. 2017 Dec;7(6):1013-1020. doi: 10.3892/mco.2017.1442. Epub 2017 Oct 4.
9
Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.肝动脉灌注化疗与索拉非尼治疗肝动脉同期放化疗后晚期肝细胞癌的疗效比较。
J Cancer Res Clin Oncol. 2021 Oct;147(10):3123-3133. doi: 10.1007/s00432-021-03632-4. Epub 2021 Apr 23.
10
Effect of body composition on survival benefit of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: A comparison with sorafenib therapy.体成分对晚期肝细胞癌肝动脉灌注化疗生存获益的影响：与索拉非尼治疗的比较。
PLoS One. 2019 Jun 13;14(6):e0218136. doi: 10.1371/journal.pone.0218136. eCollection 2019.
引用本文的文献
1
Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma.立体定向体部放射治疗（SBRT）通过增强转移性肝细胞癌小鼠的肿瘤免疫微环境来提高抗PD-1抗肿瘤活性。
Discov Oncol. 2025 Jun 13;16(1):1081. doi: 10.1007/s12672-025-02914-4.
2
The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study.肝动脉灌注化疗联合乐伐替尼及程序性死亡（PD）-1抑制剂治疗不可切除肝内胆管癌的疗效与安全性：一项回顾性研究
Curr Oncol. 2025 Feb 4;32(2):87. doi: 10.3390/curroncol32020087.
3
Current efficacy of hepatic arterial infusion chemotherapy in hepatocellular carcinoma.肝动脉灌注化疗在肝细胞癌中的当前疗效
World J Gastrointest Oncol. 2024 Dec 15;16(12):4766-4769. doi: 10.4251/wjgo.v16.i12.4766.
4
Hepatic arterial infusion chemotherapy in combination with lenvatinib and durvalumab versus standard first-line treatment gemcitabine and cisplatin plus durvalumab in advanced intrahepatic cholangiocarcinoma.肝动脉灌注化疗联合仑伐替尼和度伐利尤单抗对比标准一线治疗吉西他滨和顺铂加度伐利尤单抗治疗晚期肝内胆管癌
Am J Cancer Res. 2024 Oct 15;14(10):4922-4934. doi: 10.62347/HVOF5644. eCollection 2024.
5
Efficacy and safety of lenvatinib plus durvalumab combined with hepatic arterial infusion chemotherapy for unresectable intrahepatic cholangiocarcinoma.仑伐替尼联合度伐利尤单抗联合肝动脉灌注化疗治疗不可切除的肝内胆管癌的疗效和安全性。
Front Immunol. 2024 May 10;15:1397827. doi: 10.3389/fimmu.2024.1397827. eCollection 2024.
6
The worthy role of hepatic arterial infusion chemotherapy in combination with anti-programmed cell death protein 1 monoclonal antibody immunotherapy in advanced hepatocellular carcinoma.肝动脉灌注化疗联合抗程序性细胞死亡蛋白 1 单克隆抗体免疫治疗在晚期肝细胞癌中的重要作用。
Front Immunol. 2023 Oct 31;14:1284937. doi: 10.3389/fimmu.2023.1284937. eCollection 2023.
7
NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.NR0B1 通过促进自噬和抑制细胞凋亡增强肝癌对索拉非尼的耐药性。
Cancer Sci. 2024 Feb;115(2):465-476. doi: 10.1111/cas.16029. Epub 2023 Nov 22.
8
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations.中国肝细胞癌动脉化疗：共识推荐
Hepatol Int. 2024 Feb;18(1):4-31. doi: 10.1007/s12072-023-10599-6. Epub 2023 Oct 21.
9
Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death.肝癌细胞：杏仁苷和索拉非尼在靶向 AMPK/mTOR 和 BCL-2 以抑制血管生成和诱导细胞凋亡中的活性。
BMC Complement Med Ther. 2023 Sep 19;23(1):329. doi: 10.1186/s12906-023-04142-1.
10
Involvement and targeted intervention of benzo(a)pyrene-regulated apoptosis related proteome modification and muti-drug resistance in hepatocellular carcinoma.苯并(a)芘调控的细胞凋亡相关蛋白质组修饰与肝癌多药耐药的关系及其靶向干预。
Cell Death Dis. 2023 Apr 12;14(4):265. doi: 10.1038/s41419-023-05771-7.
本文引用的文献
1
Report of the 18th follow-up survey of primary liver cancer in Japan.日本原发性肝癌第18次随访调查报告。
Hepatol Res. 2010 Nov;40(11):1043-1059. doi: 10.1111/j.1872-034X.2010.00731.x.
2
Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging.肝硬化肝脏中肝细胞癌的无创诊断：放射影像学的当前指南与未来前景
Liver Cancer. 2012 Jun;1(1):51-8. doi: 10.1159/000339020.
3
Chemoembolization in patients with hepatocellular carcinoma.肝细胞癌患者的化疗栓塞术
Liver Cancer. 2012 Jun;1(1):41-50. doi: 10.1159/000339019.
4
Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version.日本肝细胞癌的管理：日本肝脏学会（JSH）2010 年更新版提出的基于共识的临床实践指南。
Dig Dis. 2011;29(3):339-64. doi: 10.1159/000327577. Epub 2011 Aug 9.
5
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.去γ-羧基凝血酶原可能是一种有前途的生物标志物，可用于确定索拉非尼治疗肝细胞癌的疗效。
Dig Dis. 2011;29(3):321-5. doi: 10.1159/000327570. Epub 2011 Aug 9.
6
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.索拉非尼经导管动脉化疗栓塞术后治疗不可切除的肝细胞癌的日本和韩国患者的 III 期研究。
Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.
7
Management of hepatocellular carcinoma: an update.肝细胞癌的管理：最新进展
Hepatology. 2011 Mar;53(3):1020-2. doi: 10.1002/hep.24199.
8
Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.低剂量 5-氟尿嘧啶和顺铂肝动脉灌注化疗治疗晚期肝细胞癌。
Oncology. 2010 Jul;78 Suppl 1:148-53. doi: 10.1159/000315244. Epub 2010 Jul 8.
9
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.索拉非尼在亚太地区晚期肝细胞癌患者中的疗效和安全性：一项III期随机、双盲、安慰剂对照试验。
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
10
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件